How Vygon Germany secured €200,000 in R&D funding through innoscripta’s expertise in the Forschungszulage program

Meet Vygon Germany

The Vygon Germany GmbH is a branch of the Vygon Group, a leading global business enterprise that designs and manufactures sterile single-use medical devices. The Vygon Group operates 26 subsidiaries worldwide and maintains close associations with healthcare professionals in more than 120 countries. Their expertise spans several medical specialties, including vascular, enteral, monitoring, nervous, respiratory, surgical, and urinary care.

Recognised for their quality excellence, Vygon was the first medical technology company to be certified under DIN ISO 9001 in 1991. They have obtained ISO 13485 certification for their comprehensive quality management system for the manufacture and distribution of medical devices. They also received a DSD environmental certificate, highlighting their commitment to sustainability and safety.

The Challenge

Vygon Germany faced a crucial obstacle when exploring the opportunity of the Forschungszulage. As Vygon Germany is recognised as an associated research centre of the Group’s headquarters in France, their eligibility to seek national research grants in Germany appeared impossible. After the primary analysis of the funding programme and its eligibility criteria, it seemed that pursuing the research allowance was no longer feasible and the topic was considered closed.

The Solution

After the initial consultation, the turning point happened when innoscripta provided a new solution that favourably transformed Vygon Germany's journey of seeking the research allowance. innoscripta confirmed that Vygon Germany could apply for the research allowance under the contract research category, which opened new possibilities that previously seemed inaccessible.

innoscripta also supported Vygon Germany with:

• Clarification of eligibility: innoscripta's team pointed out that contract research within production processes qualifies for the research allowance, and Vygon Germany had two active R&D projects that met the eligibility criteria to receive funding support.

• Collaborative evaluation: innoscripta evaluated all technical details of both R&D projects to ensure an exact alignment with funding requirements and guidelines.

• Expert guidance: innoscripta's structured consultation, dedicated software platform, and end-to-end support helped Vygon Germany to submit compliant funding applications to the concerned authorities.

The Impact

The collaboration with innoscripta generated remarkable outcomes for Vygon Germany within a short span of time. The comprehensive support from innoscripta created a swift process while ensuring utmost transparency, compliance, and efficiency throughout.

The key values of this partnership include:

• Efficient documentation: “Using innoscripta’s structured and clearly organized software, we were able to answer all the tax authority’s follow-up questions effectively.”

With innoscripta's project management software platform, Vygon Germany was able to record all information about their R&D projects, which enabled them to respond to all queries from the tax office promptly and therefore  led to faster funding approvals.

• Successful approval and €200,000 funding: Within six weeks of submitting the applications, the tax office granted approval that resulted in funding notices totaling €200,000, confirming the eligibility of contract research and the efficiency of innoscripta's strategic support.

Conclusion

“The collaboration with all innoscripta employees was always professional, pleasant, focused, and successful.”

Vygon Germany describes the collaboration with innoscripta as an efficient and smooth process. Emphasising the support of innoscripta's team of experts and the software platform, Vygon Germany unreservedly recommends innoscripta to any company fostering innovation and aiming to expand R&D initiatives with meritorious financial support.